Mineralys Therapeutics Common Net Income
| MLYS Stock | 30.89 1.20 3.74% |
As of the 1st of February, Mineralys Therapeutics secures the Standard Deviation of 3.8, risk adjusted performance of (0.06), and Mean Deviation of 2.4. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Mineralys Therapeutics, as well as the relationship between them. Please verify Mineralys Therapeutics information ratio and kurtosis to decide if Mineralys Therapeutics Common is priced some-what accurately, providing market reflects its recent price of 30.89 per share. Given that Mineralys Therapeutics has information ratio of (0.10), we recommend you to check Mineralys Therapeutics's last-minute market performance to make sure the company can sustain itself at a future point.
Mineralys Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Mineralys Therapeutics' valuation are provided below:There are over one hundred available fundamental ratios for Mineralys Therapeutics, which can be analyzed over time and compared to other ratios. All traders should check Mineralys Therapeutics' last-minute fundamentals against the performance from 2010 to 2026 and make sure the trends continue to evolve in the right direction. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -160 M | -152 M | |
| Net Loss | -26.8 M | -28.2 M | |
| Net Loss | -160 M | -152 M | |
| Net Loss | (4.21) | (4.42) |
Mineralys | Net Income | Build AI portfolio with Mineralys Stock |
The evolution of Net Income for Mineralys Therapeutics Common provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Mineralys Therapeutics compares to historical norms and industry peers.
Latest Mineralys Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Mineralys Therapeutics Common over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Mineralys Therapeutics financial statement analysis. It represents the amount of money remaining after all of Mineralys Therapeutics Common operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Mineralys Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Mineralys Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (177.81 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Mineralys Net Income Regression Statistics
| Arithmetic Mean | (38,156,326) | |
| Coefficient Of Variation | (163.34) | |
| Mean Deviation | 48,134,029 | |
| Median | (3,426,000) | |
| Standard Deviation | 62,325,130 | |
| Sample Variance | 3884.4T | |
| Range | 174.4M | |
| R-Value | (0.76) | |
| Mean Square Error | 1750.1T | |
| R-Squared | 0.58 | |
| Significance | 0.0004 | |
| Slope | (9,380,234) | |
| Total Sum of Squares | 62150.7T |
Mineralys Net Income History
Other Fundumenentals of Mineralys Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Mineralys Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Mineralys Therapeutics is extremely important. It helps to project a fair market value of Mineralys Stock properly, considering its historical fundamentals such as Net Income. Since Mineralys Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Mineralys Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Mineralys Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Biotechnology market expansion? Will Mineralys introduce new products? Factors like these will boost the valuation of Mineralys Therapeutics. Expected growth trajectory for Mineralys significantly influences the price investors are willing to assign. Understanding fair value requires weighing current performance against future potential. All the valuation information about Mineralys Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Mineralys Therapeutics is measured differently than its book value, which is the value of Mineralys that is recorded on the company's balance sheet. Investors also form their own opinion of Mineralys Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Mineralys Therapeutics' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Mineralys Therapeutics' market value can be influenced by many factors that don't directly affect Mineralys Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Mineralys Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Mineralys Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Mineralys Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Mineralys Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Mineralys Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Mineralys Therapeutics.
| 11/03/2025 |
| 02/01/2026 |
If you would invest 0.00 in Mineralys Therapeutics on November 3, 2025 and sell it all today you would earn a total of 0.00 from holding Mineralys Therapeutics Common or generate 0.0% return on investment in Mineralys Therapeutics over 90 days. Mineralys Therapeutics is related to or competes with Scholar Rock, Ideaya Biosciences, Adaptive Biotechnologies, Beam Therapeutics, Catalyst Pharmaceuticals, Zai Lab, and Apellis Pharmaceuticals. Mineralys Therapeutics is entity of United States More
Mineralys Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Mineralys Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Mineralys Therapeutics Common upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.10) | |||
| Maximum Drawdown | 24.81 | |||
| Value At Risk | (6.28) | |||
| Potential Upside | 5.87 |
Mineralys Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Mineralys Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Mineralys Therapeutics' standard deviation. In reality, there are many statistical measures that can use Mineralys Therapeutics historical prices to predict the future Mineralys Therapeutics' volatility.| Risk Adjusted Performance | (0.06) | |||
| Jensen Alpha | (0.40) | |||
| Total Risk Alpha | (0.54) | |||
| Treynor Ratio | (0.27) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Mineralys Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Mineralys Therapeutics February 1, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.06) | |||
| Market Risk Adjusted Performance | (0.26) | |||
| Mean Deviation | 2.4 | |||
| Coefficient Of Variation | (1,110) | |||
| Standard Deviation | 3.8 | |||
| Variance | 14.47 | |||
| Information Ratio | (0.10) | |||
| Jensen Alpha | (0.40) | |||
| Total Risk Alpha | (0.54) | |||
| Treynor Ratio | (0.27) | |||
| Maximum Drawdown | 24.81 | |||
| Value At Risk | (6.28) | |||
| Potential Upside | 5.87 | |||
| Skewness | 1.62 | |||
| Kurtosis | 6.45 |
Mineralys Therapeutics Backtested Returns
Mineralys Therapeutics has Sharpe Ratio of -0.0801, which conveys that the firm had a -0.0801 % return per unit of risk over the last 3 months. Mineralys Therapeutics exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify Mineralys Therapeutics' Risk Adjusted Performance of (0.06), standard deviation of 3.8, and Mean Deviation of 2.4 to check out the risk estimate we provide. The company secures a Beta (Market Risk) of 1.29, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Mineralys Therapeutics will likely underperform. At this point, Mineralys Therapeutics has a negative expected return of -0.31%. Please make sure to verify Mineralys Therapeutics' total risk alpha, kurtosis, as well as the relationship between the Kurtosis and market facilitation index , to decide if Mineralys Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.37 |
Below average predictability
Mineralys Therapeutics Common has below average predictability. Overlapping area represents the amount of predictability between Mineralys Therapeutics time series from 3rd of November 2025 to 18th of December 2025 and 18th of December 2025 to 1st of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Mineralys Therapeutics price movement. The serial correlation of 0.37 indicates that just about 37.0% of current Mineralys Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.37 | |
| Spearman Rank Test | 0.42 | |
| Residual Average | 0.0 | |
| Price Variance | 4.67 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Mineralys Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Mineralys Therapeutics Common reported net income of (177.81 Million). This is 152.1% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 131.14% higher than that of the company.
Mineralys Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Mineralys Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Mineralys Therapeutics could also be used in its relative valuation, which is a method of valuing Mineralys Therapeutics by comparing valuation metrics of similar companies.Mineralys Therapeutics is currently under evaluation in net income category among its peers.
Mineralys Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Mineralys Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Mineralys Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Mineralys Fundamentals
| Return On Equity | -0.42 | ||||
| Return On Asset | -0.27 | ||||
| Current Valuation | 1.95 B | ||||
| Shares Outstanding | 79.14 M | ||||
| Shares Owned By Insiders | 1.49 % | ||||
| Shares Owned By Institutions | 98.51 % | ||||
| Number Of Shares Shorted | 10.3 M | ||||
| Price To Book | 4.41 X | ||||
| EBITDA | (192.36 M) | ||||
| Net Income | (177.81 M) | ||||
| Total Debt | 14.65 M | ||||
| Book Value Per Share | 7.30 X | ||||
| Cash Flow From Operations | (166.31 M) | ||||
| Short Ratio | 7.02 X | ||||
| Earnings Per Share | (2.81) X | ||||
| Target Price | 50.88 | ||||
| Number Of Employees | 51 | ||||
| Beta | 0.5 | ||||
| Market Capitalization | 2.44 B | ||||
| Total Asset | 205.9 M | ||||
| Retained Earnings | (302.52 M) | ||||
| Working Capital | 190.71 M | ||||
| Net Asset | 205.9 M |
About Mineralys Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Mineralys Therapeutics Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mineralys Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mineralys Therapeutics Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Mineralys Stock Analysis
When running Mineralys Therapeutics' price analysis, check to measure Mineralys Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mineralys Therapeutics is operating at the current time. Most of Mineralys Therapeutics' value examination focuses on studying past and present price action to predict the probability of Mineralys Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mineralys Therapeutics' price. Additionally, you may evaluate how the addition of Mineralys Therapeutics to your portfolios can decrease your overall portfolio volatility.